Select a Region North America

인사이트

Insights From Our Experts

Articles

The Four Biggest Recruitment Issues for Clinical Operations Teams … And How to Solve Them.

Eighty percent of clinical trials in the United States fail to meet their patient recruitment timelines [1, 2] and 15-20% of activated clinical trial sites never enroll a single patient. [2] Meanwhile, 50% of clinical trial…

WHAT IF… We Broke the Silos Throughout Pre- to Post-Commercialization?

In their special November/December issue, PharmaVOICE asked industry leaders to think beyond the status quo and provide insight into what needs to happen to achieve aspirational goals and evolve the healthcare industry in 2020. In the…

Bringing Humanity Back to Healthcare

As the healthcare industry shifts to patient-centered care, PharmaVOICE asks the question: how do we bring humanity or the human element back into healthcare? As patients become more engaged healthcare consumers and patient advocacy groups more…

After FDA Approval, Can Gene Therapies Achieve Marketing Success?

Without a doubt, gene therapy is transforming healthcare by revolutionizing patient care from conventional treatment models to curative therapy models. There are more than 7,000 distinct types of rare and genetic diseases and 400+ million individuals…

Decoding ICER: Successful Pharma Engagement with ICER for U.S. HTA Review

How pharmaceutical and Biotech companies engaged ICER drives the outcome. Reactive responses to ICER review have led to poor outcomes and numerous downstream impacts to payer access and pricing. Cohesive enterprise engagement has demonstrated significantly better…

Integrated Delivery Networks: Learning to Engage With a New Customer With Very Different Needs

As the healthcare provider landscape rapidly evolves to deliver on the promises of value-based care and efficiencies of scale, integrated delivery networks (IDNs) have emerged as a dominant force in the US market. Meanwhile, biopharmaceutical manufacturers…

Challenges and Best Practices in Managing Value Based Contracts

Manufacturers face a variety of hurdles when negotiating value based contracts: from data access and standardization, deal structure variation, payment variability and scheduling, to changing laws and regulations. And, as the industry shifts to value-driven healthcare,…

white paper-insights
Gross-to-Net Improvement Through Holistic Revenue Enhancement

Consistent price increases have long been a staple of commercial strategy for pharmaceutical manufacturers. From this uplift in topline revenue, more sizable discounts can be provided to industry middlemen, like pharmacy benefit managers (PBMs), in order…

Navigating the Cycle of Supply Chain Complexity

As the industry evolves with new regulatory guidelines and product-specific handling requirements, manufacturers now require an agile business model with integrated distribution services. In his new point of view article, Danny Williams, explains how manufacturers can…

Global Biosimilar Competitor Assessment – Who Wins in Biosimilar Access and Why?

The introduction of biosimilar products has created interesting changes in payer behavior across the global markets. For both innovator and biosimilar companies, it has been an effort to understand the demands of payers and succeed in…